Mauna Kea Technologies SA manufactures and sells medical devices in Europe and internationally. It offers a range of medical devices for gastroenterology, pulmonology, and urology applications. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform that enables unique in vivo cellular visualization, allowing doctors to monitor disease evolution over time, evaluate reactions as they occur, classify areas of uncertainty, guide surgical interventions, and help diagnose and treat patients. The company was incorporated in 2000 and is headquartered in Paris, France.
Frequently asked questions
What sector does Mauna Kea Technologies SAS (ALMKT) operate in?
Mauna Kea Technologies SAS belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Mauna Kea Technologies SAS (ALMKT) current stock price?
As of the latest data, Mauna Kea Technologies SAS stock price is €0.15, with a previous close of €0.15.
What is Mauna Kea Technologies SAS (ALMKT) current market capitalization?
Mauna Kea Technologies SAS market cap is approximately 29.13 million.
What is Mauna Kea Technologies SAS (ALMKT) Earnings Per Share (EPS)?
The trailing EPS is €0.10.
What is Mauna Kea Technologies SAS (ALMKT) Price-to-Earnings (P/E) ratio?
Mauna Kea Technologies SAS current P/E ratio is 1.49.
Does Mauna Kea Technologies SAS (ALMKT) pay dividends?
No. Mauna Kea Technologies SAS does not pay a dividend.
What is Mauna Kea Technologies SAS (ALMKT) beta (volatility) score?
Mauna Kea Technologies SAS has a beta of 0.944, meaning its volatility is roughly in line with the market.
